Disseminated intravascular coagulation: Clinical spectrum and established as well as new diagnostic approaches

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 706-712

  Müller Berghaus, Gert ^a   Ten Cate, Hugo ^b   Levi, Marcel ^c  

^a KERCKHOFF HEART CENTER   (Germany)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; D DIMER; FIBRIN; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; PLASMIN; PLASMINOGEN; THROMBIN ANTITHROMBIN COMPLEX;

CLINICAL FEATURE; CONFERENCE PAPER; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; LABORATORY DIAGNOSIS; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; SYNDROME DELINEATION; THROMBIN TIME; THROMBOCYTE COUNT;

EID: 0032741946     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615900     Document Type: Conference Paper

References (45)

1. McKay DG. Disseminated Intravascular Coagulation. An Intermediary Mechanism of Disease. New York: Hoeber Medical Division,Harper and Row 1964;715-728.
2. Müller-Bergbaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways. Sem Thromb Hemostas. 1989;15:58-87.
3. Müller-Berghaus G, Madlener K, Blombäck M., ten Cate JW, eds. DIC. Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation. Amsterdam: Elsevier Science Publishers B.V., 1993.
4. Bick RL. Disseminated intravascular coagulation. Objective laboratory diagnostic criteria and guidelines for management. Clin Lab Med. 1994;14:729-768.
5. Schneider CL. Thromboplastin complications of late pregnancy. In: A Ciba Foundation Symposium, ed. Toxaemias of pregnancy. Human and veterinary. London: Churchill, 1950:163-181.
6. Ratnoff OD, Conley CL. Studies on afibrinogenemia. II. The defibrinating effect on dog blood of intravenous injection of thromboplastin material. Bull Johns Hopk Hosp 1951;88:414-424.
7. Quick AJ, Hussey CV, Harris J, Peters K. Occult intravascular clotting by means of intravenous injection of thrombin. Am J Physiol. 1959;197:791-794.
8. Margaretten W, Zunker HO, McKay DG. Production of the generalized Shwartzman reaction in pregnant rats by intravenous infusion of thrombin. Lab Invest. 1964;13:552559.
9. Müller-Bergbaus G, Róka L, Lasch HG. Induction of glomerular microclot formation by fibrin monomer infusion. Thromb Diath Haemorrh. 1973;29:375-383.
10. Lasch HG, Krecke H-J, Rodriguez-Erdmann F, Sessner HH, Schütterle G. Verbrauchskoagulopathien (Pathogenese und Therapie). Folia haemat. (NF) 1961;6:325-330.
11. Lasch H-G, Heene DL, Huth K, Sandritter W. Pathophysiology, clinical manifestations and therapy of consumption-coagulopathy ("Verbrauchskoagulopathie"). Am J Cardiol. 1967;20:381-391.
12. Alkjaersig N, Fletcher AP, Sherry S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization. J Clin Invest. 1962;41:917-934.
13. Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med. 1993;119:819-827.
14. Bauer KA. Hypercoagulable states. In: Hoffman R, Benz Jr. EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, eds. Hematology. Basic principles and practice. 2nd Ed. New York: Churchill Livingstone, 1995:1781-1795.
15. Merlini PA, Bauer KA, Mannucci PM. Laboratory detection of the prethrombotic state. In: Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. 2nd Ed. Philadelphia: Lippincott-Raven Publishers, 1998:103-118.
16. Müller-Bergbaus G, Scheefers-Borchel U, Fuhge P, Eberle R, Heimburger N. Detection of fibrin in plasma by a monoclonal antibody against the amino-terminus of the a-chain of fibrin. Scand J Clin Lab Invest. 1985;45 (Suppl 178):145-151.
17. Scheefers-Borchel U, Müller-Bergbaus G, Fuhge P, Eberle R, Heimburger N. Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide. Proc Natl Acad Sci USA. 1985;82:7091-7095.
18. Bredbacka S, Blombäck M. Soluble fibrin - a predictor for development and outcome of multiple organ failure. In: Müller-Berghaus G, Madlener K, Blombäck M, ten Cate JW, eds. DIC. Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation. Amsterdam: Excerpta Medica, 1993:111-112.
19. Stibbe J, Gomes M, de Oude A. The value of the FM-test (KABI) and thrombin-antithrombin-III complexes (TAT) in the management of DIC in cancer. Thromb Haemostas. 1991;65:1238
20. Dempfle CE, Pfitzner SA, Dollman M, Huck K, Stehle G, Heene DL. Comparison of immunological and functional assays for measurement of soluble fibrin. Thromb Haemostas. 1995;74:673-679.
21. Okajima K, Uchiba M, Murakami K, Okabe H, Takatsuki K. Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation. Am J Hematol. 1996;51:186-191.
22. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Deguchi H, Mon Y, Kaneko T, Deguchi K, Fujii J, Shiku H. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol. 1996;51:255-260.
23. Pfitzner SA, Dempfle CE, Matsuda M, Heene DL. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A. Thromb Haemoss. 1997;78:1069-1078.
24. Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemost. 1980;43:28-33.
25. 2-plasmin inhibitor, fibronectin, prothrombin, and protein C. Arch Intern Med. 1986;146:1997-2002.
26. Bovill EG. Disseminated intravascular coagulation: pathophysiology and laboratory diagnosis. Fibrinolysis. 1993;7(Suppl.2):17-19.
27. Williams EC, Mosher DF. Disseminated intravascular coagulation. In: Hoffman R, Benz Jr. EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, eds. Hematology. Basic Principles and Practice. 2nd Ed. New York: Churchill Livingstone, 1995:1758-1769.
28. Bick RL. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Sem Thromb Hemostas. 1996;22:69-88.
29. Müller-Berghaus G, ten Cate H, Levi M. Disseminated intravascular coagulation. In: Verstraete M, Fuster V, Topol E, eds. Cardiovascular Thrombosis: Thrombocardiology. 2nd Ed. Philadelphia: Lippincott-Raven, 1998:781-799.
30. Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Sem Thromb Hemostas. 1998;24:3-18.
31. Takahashi H, Tatewaki W, Wada K, Niwano H, Shibata A. Fibrinolysis and fibrinogenolysis in disseminated intravascular coagulation. Thromb Haemostas. 1990;63:340-344.
32. Fukutake K, Kuroso K, Isogai N, Shinozawa K. Clinical evaluation of D-dimer testing in disseminated intravascular coagulation (DIC). Fibrinolysis. 1993;7(Suppl.2):20-22.
33. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Mori Y, Shiku H. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost. 1995;74:848-852.
34. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor Vila and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood. 1996;88:881-886.
35. Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, van Deventer SJH, ten Cate JW. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost. 1995;73:15-20.
36. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost. 1996;75:224-228.
37. Mesters RM, Flörke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost. 1996;75:902-907.
38. Mersky C, Johnson AJ, Kleiner GJ. The defibrination syndrome: Clinical features and laboratory diagnosis. Br J Haematol. 1967;13:528
39. Lane DA, Preston FE, van Ross ME, Kakkar VV. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation. Br J Haematol. 1978;40:609-615.
40. Nieuwenhuizen W. Degradation of fibrinogen and its derivatives in the course of disseminated intravascular coagulation. In: Müller-Bergbaus G, Madlener K, Blombäck M, ten Cate JW, eds. DIC. Pathogenesis, diagnosis and therapy of disseminated intravascular fibrin formation. Amsterdam: Excerpta Medica, 1993:117-123.
41. 2-plasmin inhibitor-plasmin complexes. Blood. 1983;61:842-849.
42. 2-antiplasmin complex in human plasma - Application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemost. 1986;56:124-127.
43. 2 -antiplasmin activity. Role in the evaluation and management of fibrinolytic states and other bleeding disorders. Arch Intern Med. 1989;149:1769-1772.
44. 2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation. Am J Hematol. 1988;28:162-166.
45. van der Poll T, Levi M, Buller HR, van Deventer SJ, de Boer JP, Hack CE, ten Cate JW. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med. 1991;174:729-732.